Skip to main content
. 2017 Jul 3;9(9):1294–1313. doi: 10.15252/emmm.201607315

Figure 6. MG132 reduces progerin and SRSF‐1 levels in patient iPS‐Derived MSC and VSMC.

Figure 6

  1. Immunofluorescence images of HGPS‐derived iPS‐VSMC and WT‐derived iPS‐VSMC cultured with DMEM medium containing either indicated MG132 concentrations (0.15, 0.31, 0.62, 1.25, 2.5, 5, and 10 μM) or DMSO (0) for 24 h and stained for progerin (green). Scale bar, 40 μm. (n = 3).
  2. MG132 treatment resulted in a decrease of progerin levels. A representative Western blotting experiment in whole lysates showing progerin, actin, GAPDH, SRSF‐1, LC3B‐I, and LC3B‐II expression in 5 μM MG132‐treated HGPS fibroblasts (+), 2.5 μM MG132‐treated HGPS iPS‐MSC (+), and 1.2 μM MG132‐treated HGPS iPS‐VSMC (+) for 24 h, relative to DMSO‐treated cells (−). (n = 4).
  3. HGPS‐derived iPS‐MSC and iPS‐VSMC viability was measured at 24 h post‐treatment with MG132 at the indicated concentrations using CellTiter‐Glo Luminescent Cell Viability Assay. Results are reported as viability percentage of MG132‐treated cells relative to DMSO‐treated cells. Results are expressed as mean ± SEM (n = 4).

Source data are available online for this figure.